Skip to content

Pelvic Congestion Syndrome and Endometriosis

Ultrasound Evaluation of the Prevalence of Pelvic Congestion Syndrome in Patients With Endometriosis

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03568149
Acronym
VES
Enrollment
160
Registered
2018-06-26
Start date
2018-12-14
Completion date
2019-08-31
Last updated
2019-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis, Pelvic Congestive Syndrome

Brief summary

The pelvic congestion syndrome (PCS) is a complex and multifactorial condition associated with inflammatory and hormonal etiophatogenesis similar to the endometriosis. Furthermore, both pathologies share same clinical symptoms as chronic pelvic pain and dyspareunia. Our hypothesis is that PCS prevalence is higher in patients with endometriosis than in those without clinical or ultrasound signs of endometriosis.

Detailed description

Patients undergoing routine gynecological examinations are included in the study. Patients are divided into 2 groups: * Group A: with endometriosis * Group B: without clinical or ultrasound signs of endometriosis This is an observational, monocentric, prospective, exploratory study. The aim is to assess PCS incidence, associated symptoms and ultrasound characteristics in patients with endometriosis and to compare those findings to those of patients who do not present clinical or ultrasound signs of endometriosis. The study also evaluates the correlation between: * Type of pain symptoms (dysmenorrhea, chronic pelvic pain, ovulation pain, dyspareunia, dysuria, dyschezia) and PCS * Pain severity (assessed according to VAS scale from 0= no pain to 10= unbearable pain) and PCS * Symptoms and ongoing medical treatments * History of pelvic surgery and PCS. Ultrasound parameters of pelvic vascular insufficiency are: * Ovarian vein diameter \<4mm * Slow ovarian blood flow (\<3cm/sec) * Retrograde blood flow * Dilated arcuate veins communicating with pelvic varices * The presence of pelvic varices is evaluated qualitatively as normal, moderate and serious This evaluation includes the study of uterine and ovarian vessels, using different techniques: * Standard 2D study: it allows to measure vessels diameter * Vascular doppler study: it allows to evaluate flow direction and blood speed * 3D color study: it allows a three- dimensional reconstruction of vessels and a more accurate qualitative assessment of the congestion degree. * Ultrasound images are evaluated independently by two operators.

Interventions

PROCEDUREassessment of pain symptoms at first medical examination

First medical examination consists of collection of medical history and standard gynecological examination (bimanual gynecological examination and abdominopelvic ultrasounds). Data regarding age, Body Mass Index, ongoing hormone therapy and pelvic pain symptoms, assessed according to Visual Analogue Scale (VAS) (from 0= no pain to 10= unbearable pain), are collected. The presence of perineal or lower limb varices and the presence and localization of evoked pain at bimanual gynecological examination are also evaluated.

PROCEDUREassessment of pelvic vascular insufficiency signs

Assessment of pelvic vascular insufficiency in conducted using abdominopelvic ultrasounds, according to the following parameters: * Ovarian vein diameter \<4mm * Slow ovarian blood flow (\<3cm/sec) * Retrograde blood flow * Dilated arcuate veins communicating with pelvic varices The presence of pelvic varices is evaluated qualitatively as normal, moderate and serious This evaluation includes the study of uterine and ovarian vessels, using different techniques: * Standard 2D study, to measure vessels diameter * Vascular doppler study, to evaluate flow direction and blood speed * 3D color study, for a three- dimensional reconstruction of vessels and a more accurate qualitative assessment of the congestion degree.

Sponsors

IRCCS Azienda Ospedaliero-Universitaria di Bologna
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

(Group A): * Obtaining Informed Consent * Nulliparity * Clinical or ultrasounds signs of endometriosis Inclusion Criteria (Group B): * Obtaining Informed Consent * Nulliparity

Exclusion criteria

* Menopause * Actual or previous pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Incidence of pelvic congestive syndrome in patients with endometriosis1 day, first medical examinationComparison of pelvic congestive syndrome symptoms and ultrasounds characteristics, assessed by standard gynecological examination (bimanual gynecological examination and gynecological ultrasounds), between patients with endometriosis (Group A) and without clinical or ultrasound signs of endometriosis.

Secondary

MeasureTime frameDescription
Correlation between type of pain and pelvic congestive syndrome1 day, first medical examinationEvaluation of the type of pain (dysmenorrhea, chronic pelvic pain, ovulation pain, dyspareunia, dysuria, dyschezia) presented by patients with pelvic congestive syndrome.
Correlation between pain severity and pelvic congestive syndrome1 day, first medical examinationEvaluation of a possible correlation between pain severity and the presence of pelvic congestive syndrome. Pain severity is assessed according to Visual Analogue Scale (VAS scale from 0= no pain to 10= unbearable pain).
Correlation between symptoms and ongoing medical treatments1 day, first medical examinationEvaluation of a possible correlation between symptoms and ongoing medical treatments in patients with pelvic congestive syndrome
Correlation between history of pelvic surgery and pelvic congestive syndrome1 day, first medical examinationEvaluation of a possible correlation between history of pelvic surgery and the presence of pelvic congestive syndrome

Countries

Italy

Contacts

Primary ContactDiego Raimondo
die.raimondo@gmail.com00390512144385

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026